Portal de Periódicos da CAPES

The immunopeptidomic landscape of ovarian carcinomas

2017; National Academy of Sciences; Volume: 114; Issue: 46 Linguagem: Inglês

10.1073/pnas.1707658114

1091-6490

Heiko Schuster, Janet K. Peper-Gabriel, H. Bösmüller, Kevin Röhle, Linus Backert, Tatjana Bilich, Britta Ney, Markus Löffler, Daniel J. Kowalewski, Nico Trautwein, Armin Rabsteyn, Tobias Engler, Sabine Braun, Sebastian P. Haen, Juliane S. Walz, Barbara D. Schmid-Horch, Sara Y. Brucker, D. Wallwiener, Oliver Kohlbacher, Falko Fend, Hans‐Georg Rammensee, Stefan Stevanović, Annette Staebler, Philipp Wagner,

CAR-T cell therapy research

Significance Despite the revolution in cancer therapy initiated by checkpoint inhibitors, durable clinical responses remain sporadic in many types of cancer, including ovarian cancer. Understanding which antigens are essentially presented by tumor cells and further able to be recognized by T cells provides a major step toward novel effective targeted immunotherapies. In this study, we comprehensively analyzed the immunopeptidomic landscape of ovarian carcinoma and compared it to variety of benign sources to identify antigens exclusively presented on tumor cells. With personalized therapies moving into the focus of clinical cancer therapy, we further present insights on how gene-expression analysis and immunohistochemistry can support antigen selection for individualized immunotherapy.